Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
By Andrew M. Seaman NEW YORK (Reuters Health) – Low-dose aspirin, even if not taken daily, may reduce a woman’s risk of colon cancer over the long term,…
NEW YORK (Reuters Health) – Physicians caring for women who are at increased risk for breast cancer should discuss with them the risks and benefits of specific chemoprevention…
By David Douglas NEW YORK (Reuters Health) – Mammalian target of rapamycin (mTOR) inhibitor treatment has been linked with acute tubular necrosis (ATN) in four case reports from…
Salim Ismail, Founding Executive Director, Singularity University, gives you the top 5 medical breakthroughs by 2020 that will revolutionize medicine in the healthcare sector. Read more about Salim…
Jack Andraka, recipient of the 2012 Gordon E. Moore Award, explains the process of developing a cheap, fast, and 100% accurate diagnostic test for pancreatic cancer. Drawing from…
NEW YORK (Reuters Health) – A small study indicates that most patients with cutaneous B-cell lymphoma who respond well to rituximab relapse after about two years. On the…
NEW YORK (Reuters Health) – Contrary to a historically pessimistic outlook, high-risk prostate cancer can be controlled with moderate high-dose radiation treatment and prolonged androgen-deprivation therapy (ADT). That…
By Will Boggs, MD NEW YORK (Reuters Health) – Carboplatin plus pemetrexed improves survival over pemetrexed alone in ambulatory patients with advanced non-small-cell lung cancer (NSCLC), randomized trial…
NEW YORK (Reuters Health) – An updated meta-analysis supports the strategy of giving intravesical chemotherapy (IVC) immediately after bladder tumor resection to reduce the risk of recurrence. “However,…
NEW YORK (Reuters Health) – The cumulative incidence of osteonecrosis of the jaw was about 2% over 6 years among women with early breast cancer who received intensive…
